Effect of Helicobacter pylori eradication on gastric cancer prevention in Korea: A randomized controlled clinical trial

ational Cancer Center0 个研究点目标入组 5,224 人开始时间: 待定最近更新: 2020年2月24日

适应症

试验速览

暂无简介。

•Men and women aged 40-65 who are invited to participate in the National Cancer - Screening Program and receive upper endoscopy
•- Willingness to sign an informed consent form
•- Good health, as determined by medical history and physical examination at enrollment

•- Personal history of gastric cancer
•- Family history of gastric cancer in a first degree relative
•- Diagnosis and active treatment for other organ cancer except carcinoma in situ within 5 years
•- Current treatment for serious medical condition which could hinder participation (such as liver cirrhosis, renal failure, pulmonary dysfunction including COPD or asthma, or uncontrolled infection)
•- Inadequate cardiovascular function including (a) New York Heart Association class III or IV heart disease, (b) unstable angina or myocardial infarction history, (c) history of significant ventricular arrhythmia requiring medication with antiarrhythmics, and (d) history of cerebrovascular accident
•- Requirement for therapeutic anticoagulant therapy, aspirin
•- Gastric resections due to benign disease
•- H. pylori eradication therapy history
•- Mental incompetence to understand and sign informed consent
•- Alcoholism, drug abuse
•- Serious chronic diseases according to the evaluation of the study physician
•- Presence of a contraindication to the use of eradication treatment regimens
•- Inability to provide an informed consent
•- Pregnant or lactating women
•- Treatment required due to peptic ulcer, gastric cancer or esophageal cancer identified during the endoscopic examination

发起方

ational Cancer Center